Skip to main content
Passa alla visualizzazione normale.


Primary HBB gene mutation severity and long-term outcomes in a global cohort of β-thalassaemia

  • Authors: Musallam K.M.; Vitrano A.; Meloni A.; Addario Pollina S.; Di Marco V.; Hussain Ansari S.; Filosa A.; Ricchi P.; Ceci A.; Daar S.; Vlachaki E.; Singer S.T.; Naserullah Z.A.; Pepe A.; Scondotto S.; Dardanoni G.; Karimi M.; El-Beshlawy A.; Hajipour M.; Bonifazi F.; Vichinsky E.; Taher A.T.; Sankaran V.G.; Maggio A.
  • Publication year: 2021
  • Type: Articolo in rivista
  • OA Link:


In β-thalassaemia, the severity of inherited β-globin gene mutations determines the severity of the clinical phenotype at presentation and subsequent transfusion requirements. However, data on associated long-term outcomes remain limited. We analysed data from 2109 β-thalassaemia patients with available genotypes in a global database. Genotype severity was grouped as β0/β0, β0/β+, β+/β+, β0/β++, β+/β++, and β++/β++. Patients were followed from birth until death or loss to follow-up. The median follow-up time was 34·1 years. Mortality and multiple morbidity outcomes were analyzed through five different stratification models of genotype severity groups. Interestingly, β0 and β+ mutations showed similar risk profiles. Upon adjustment for demographics and receipt of conventional therapy, patients with β0/β0, β0/β+, or β+/β+ had a 2·104-increased risk of death [95% confidence interval (CI): 1·176–3·763, P = 0·011] and 2·956-increased odds of multiple morbidity (95% CI: 2·310–3·784, P < 0·001) compared to patients in lower genotype severity groups. Cumulative survival estimates by age 65 years were 36·8% for this subgroup compared with 90·2% for patients in lower genotype severity groups (P < 0·001). Our study identified mortality and morbidity risk estimates across various genotype severity groups in patients with β-thalassaemia and suggests inclusion of both β+ and β0 mutations in strata of greatest severity.